CRISPR in Cancer Biology and Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 15 July 2024 | Viewed by 7032
Special Issue Editor
Interests: cancer drug resistance; targeted-therapy; CRISPR screens; CRISPR-related technology; base eating; gene editing; prime editing; off-target analysis; AAV delivery
Special Issue Information
Dear Colleagues,
Cancer is a disease of the genome, initiated by the activation of oncogenes and the inactivation of tumor suppressors. It is also a disease of the cell, feeding off changes in metabolism and motility to be able to grow in different environments. Understanding how genomic changes drive the initiation of individual cancers is crucial for developing more effective treatment options and improving outcomes for cancer patients.
CRISPR has been realized as a tool for programmable genome modification in almost all cell types. The development of different CRISPR-mediated genome editing tools continues to drive major advances in the life sciences. Currently, four classes of CRISPR-Cas-derived genome editing agents—nucleases, base editors, transposases and prime editors—are currently available for modifying genomes. Each of them has its own capabilities, and a lot of efforts have expanded their targeting scope and enhanced editing specificity.
In cancer research, CRISPR-related tools have greatly advanced our understanding of cancer genetics and tumor heterogeneity, providing new insights into therapeutic vulnerabilities. This Special Issue will focus on the development of CRISPR systems as a tool to study cancers, and the emerging adaptation of these technologies to improve diagnosis and treatment.
Dr. Shunqing Liang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer drug resistance
- CRISPR screens
- CRISPR-related technology
- base editing
- prime editing
- off-target analysis
- adeno-associated virus